New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group
Keywords: Non squamous NSCLC; Second line therapy; Nintedanib; Ramucirumab; Nivolumab; Pembrolizumab; Atezolizumab; Docetaxel; Therapeutic strategy;